Abstract
Disparities in invasive cervical cancer (ICC) incidence exist globally, particularly in HIV positive women who are at elevated risk compared to HIV negative women. We aimed to determine the spatial, temporal, and spatiotemporal incidence of ICC and the associated factors among HIV positive women in South Africa. We included ICC cases in women diagnosed with HIV from the South African HIV cancer match study during 2004-2014. We used the Thembisa model to estimate women diagnosed with HIV per municipality, age group and calendar year. We fitted Bayesian hierarchical models to estimate the spatiotemporal distribution of ICC incidence among women diagnosed with HIV. We also examined the association of deprivation, access to health (using the number of health facilities per municipality) and urbanicity with ICC incidence. We included 17,821 ICC cases and demonstrated a decreasing trend in ICC incidence, from 306 to 312 in 2004 and from 160 to 191 in 2014 per 100,000 person-years across all corrections. The spatial relative rate (RR) ranged from 0.27 to 4.43. In the model adjusting for covariates, the most affluent municipalities had a RR of 3.18 (95% Credible Interval 1.82, 5.57) compared to the least affluent ones, and municipalities with better access to health care had a RR of 1.52 (1.03, 2.27) compared to municipalities with worse access to health. More efforts should be made to ensure equitable access to health services, including mitigating physical barriers, such as transportation to health centres and strengthening of screening programmes.
Novelty and Impact This is the first nationwide study in South Africa to evaluate spatial and spatiotemporal distribution of cervical cancer in women diagnosed with HIV. The results show an increased incidence of cervical cancer in affluent municipalities and in those with better access to health care. This is likely driven by better access to health care in more affluent areas. More efforts should be made to ensure equitable access to health services, including mitigating physical barriers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Institute Of Diabetes And Digestive And Kidney Diseases (NIDDK), National Institute On Drug Abuse (NIDA), National Heart, Lung, And Blood Institute (NHLBI), National Institute On Alcohol Abuse And Alcoholism (NIAAA), Fogarty International Center (FIC), National Cancer Institute (NCI), and by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI069924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this publication was supported by the National Institutes of Health administrative supplement to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp) (The South African HIV Cancer Match Study; U01AI069924-09, PI Matthias Egger, co-PI Julia Bohlius) PEPFAR supplement (PI Matthias Egger), the Swiss National Science Foundation (The South African HIV Cancer Match Study, 320030_169967, PI Julia Bohlius) and the U.S. CRDF Global (Beginning Investigator Grant for Catalytic Research in Cancer, Burden of Cancers Associated with HIV_DAA3-16-62705-1, PI Mazvita Sengayi), and allocated for this project. The contents are solely the responsibility of the authors and do not necessarily reflect the views of the funding bodies. Garyfallos Konstantinoudis is supported by an MRC Skills Development Fellowship [MR/T025352/1]. This project has received funding from the European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 801076, through the SSPH+ Global PhD Fellowship Programme in Public Health Sciences (GlobalP3HS) of the Swiss School of Public Health (PhD Candidate: Tafadzwa Dhokotera).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Permission to use the routinely collected NHLS and NCR data was sought from the relevant authorities. Ethical approval to conduct the study was granted by the University of the Witwatersrand Human Research Ethics Committee [Ethics certificate number (SAM: M160944)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data will be made available as aggregated data. Additional data can be granted upon reasonable request
